Genprex to Participate in CEO Roadshow Webinar Series
April 21 2021 - 8:30AM
Business Wire
Webinar series will feature a weekly company
overview highlighting the Genprex’s gene therapy pipeline in cancer
and diabetes
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced that its President and Chief Executive Officer,
Rodney Varner, will be participating in a webinar series with CEO
Roadshow to provide a company overview to investors on a weekly
basis from April 22 through June 10, 2021.
Details for the weekly CEO Roadshow webinar series:
Host: CEO Roadshow Date: Once per week, each
Thursday, from April 22 through June 10, 2021 Time:
Thursdays from 11-11:30 a.m. EDT Webinar Link:
https://bit.ly/3eoHeie
Mr. Varner will be available for questions following each
company presentation. The webinars will be recorded and available
for replay on Genprex’s website for a period of time. Replays will
also be available on CEORoadshow.com following each webinar. The
CEO Roadshow webinar series features small and mid-cap stocks that
are on the verge of a breakout or have other near-term developments
making them an attractive long-term investment opportunity.
About Genprex, Inc. Genprex, Inc. is a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes. Genprex’s technologies are
designed to administer disease-fighting genes to provide new
therapies for large patient populations with cancer and diabetes
who currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. The Company’s lead product
candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated
as a treatment for non-small cell lung cancer (NSCLC). REQORSA has
a multimodal mechanism of action that has been shown to interrupt
cell signaling pathways that cause replication and proliferation of
cancer cells; re-establish pathways for apoptosis, or programmed
cell death, in cancer cells; and modulate the immune response
against cancer cells. REQORSA has also been shown to block
mechanisms that create drug resistance. In January 2020, the U.S.
Food and Drug Administration granted Fast Track Designation for
REQORSA for NSCLC in combination therapy with AstraZeneca’s
Tagrisso® (osimertinib) for patients with EFGR mutations whose
tumors progressed after treatment with Tagrisso alone.
For more information, please visit the Company’s web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are made on the basis of the
current beliefs, expectations and assumptions of management, are
not guarantees of performance and are subject to significant risks
and uncertainty. These forward-looking statements should,
therefore, be considered in light of various important factors,
including those set forth in Genprex’s reports that it files from
time to time with the Securities and Exchange Commission and which
you should review, including those statements under “Item 1A – Risk
Factors” in Genprex’s Annual Report on Form 10-K.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
the timing and success of Genprex’s clinical trials and regulatory
approvals; the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes; Genprex’s
future growth and financial status; Genprex’s commercial and
strategic partnerships including the scale up of the manufacture of
its product candidates; and Genprex’s intellectual property and
licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210421005354/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024